Clinical trials: Cancer, Advanced
Prostate Cancer
Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer
RATIONALE: Antiandrogen withdrawal may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of ketoconazole and hydrocortisone for antiandrogen withdrawal in treating men…
- Trial name
- NCT00002760
- Testing
- ketoconazole, therapeutic hydrocortisone, Withdrawal of antiandrogen therapy
- Where
- 2 sites in United States
- Volunteers
- 260 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Advanced Data-Aided Medicine Part Lung Cancer
Developing and validating an AI model that supports physicians in their decision process for treating lung cancer patients. This AI model needs to predict the probability of (the evolution of) the outcomes, based on clinical data…
- Trial name
- ADAMpartlung (NCT05783024)
- Testing
- Data collection
- Where
- Belgium
- Volunteers
- 500 people
- Sponsor
- AZ Delta
Locally Advanced Cervical Cancer
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have…
- Trial name
- eVOLVECervical (NCT06079671)
- Testing
- Volrustomig
- Where
- 205 sites in United States, Brazil and 17 more
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Advanced or Metastatic Colorectal Cancer (mCRC)
Individual Patient Expanded Access to CA102N
This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.
- Trial name
- NCT05274204
- Testing
- CA102N
- Sponsor
- Holy Stone Healthcare Co., Ltd
Gastric Cancer, Gastroesophageal-junction Cancer
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Purpose of this study is to define the maximal tolerated dose (MTD) and recommended phase 2 dose (RP2D) of paclitaxel and tepotinib combination therapy in patients with advanced tumors and to evaluate the efficacy of paclitaxel…
- Trial name
- NCT05439993
- Testing
- Tepotinib plus paclitaxel
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Hallym University Medical Center
Non-Clear Cell Renal Cell Carcinoma
Personalized ctDNA Monitoring for Predicting Immunotherapy Outcomes in Advanced Non-Clear Cell Renal Cell Carcinoma
This is a prospective, non-interventional observational cohort study evaluating the clinical utility of patient-specific circulating tumor DNA (ctDNA) monitoring in patients with advanced non-clear cell renal cell carcinoma…
- Trial name
- NCT07776483
- Testing
- Patient-Specific Tumor-Informed ctDNA Monitoring
- Volunteers
- 67 people
- Sponsor
- West China Hospital
Ewing's Tumor Metastatic
Anlotinib and Irinotecan for Ewing Sarcoma
The investigators explored the activity of anlotinib combined with irinotecan in patients with relapsed and metastatic Ewing Sarcoma.
- Trial name
- NCT03416517
- Testing
- Anlotinib, Irinotecan
- Where
- 5 sites in China
- Volunteers
- 47 people
- Sponsor
- Peking University People's Hospital
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Stage IIB, Cervical Cancer Stage IIIA
Clinical Trial of Laparoscopic Pelvic and Para-aortic Lymphadenectomy and Uterine Blood Vessel Blocking for Precision Diagnosis and Treatment in Advanced Cervical Cancer
Cervical cancer is the most common reproductive malignancy in developing country. Due to local invasion, radical hysterectomy cannot be performed in advanced cervical cancer (FIGO IIB - IVA) , so that radiation combined with…
- Conditions
- Cervical Cancer, Stage IIB, Cervical Cancer Stage IIIA, Cervical Cancer Stage IIIB, Cervical Cancer, Stage IVA
- Trial name
- NCT02950350
- Volunteers
- 50 people
- Sponsor
- Shanghai First Maternity and Infant Hospital
Colorectal Neoplasms
Stivarga Regulatory Post-Marketing Surveillance Study in Korea
To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.
- Trial name
- StivargaPMS (NCT02106858)
- Testing
- Regorafenib (Stivarga,BAY73-4506)
- Where
- South Korea
- Volunteers
- 316 people
- Sponsor
- Bayer
Cancer
Study of PBF-999 in Solid Tumour Advanced Cancer
Multicentric phase I (dose escalation plus expansion) clinical trial of PBF-999 in patients with immunotherapy naïve and pretreated solid tumors to evaluate the safety, tolerability and preliminary efficacy of the compound
- Trial name
- NCT03786484
- Testing
- PBF-999
- Where
- Spain
- Volunteers
- 54 people
- Sponsor
- Palobiofarma SL
Neoplasms
Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
It is a non-randomized, multicentric, cohort study, combined with a biological sample collection, a clinical data collection and with a genetic and immunologic biomarkers study.
- Trial name
- PROFILER (NCT01774409)
- Testing
- Blood and tumor samples
- Where
- 6 sites in France
- Volunteers
- 10,000 people
- Sponsor
- Centre Leon Berard
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL
Patients on this study have a type of lymph gland cancer called non-Hodgkin Lymphoma or chronic Lymphocytic Leukemia. Their lymphoma or CLL has come back or has not gone away after treatment.
- Trial name
- ATECRAB (NCT00709033)
- Testing
- autologous or syngeneic PBTLs and EBV-CTLs
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Baylor College of Medicine
Sarcoma
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide or doxorubicin is more effective for advanced or metastatic soft…
- Trial name
- NCT00003212
- Testing
- doxorubicin hydrochloride, ifosfamide
- Where
- 23 sites in Belgium, Denmark and 8 more
- Volunteers
- 780 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan
This is an observational study in which data from the past of people with solid tumors harboring an NTRK gene fusion in Japan are studied.
- Trial name
- NCT05793281
- Testing
- No Drug
- Where
- Japan
- Volunteers
- 46,621 people
- Sponsor
- Bayer
Renal Cancer Metastatic
A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma
Phase II clinical trial to investigate the safety, clinical activity and toxicity of combinations of D-CIK and low dose anti-PD-1 antibody in patients with metastatic renal cell carcinoma treated with axitinib.
- Trial name
- NCT03736330
- Testing
- Combinations treatment
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of 9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced sarcoma.
- Conditions
- Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Leiomyosarcoma
- Trial name
- NCT05116800
- Testing
- Gemcitabine, 9-ING-41, Docetaxel
- Where
- 2 sites in United States
- Sponsor
- Brown University
Advanced Unresectable Solid Tumors, BRAF-mutated Tumors
A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of FORE8394.
- Trial name
- NCT02428712
- Testing
- FORE8394
- Where
- 13 sites in United States
- Volunteers
- 113 people
- Sponsor
- Fore Biotherapeutics
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma
Biomarkers in Patients With Advanced Rhabdomyosarcoma
This research trial studies tumor tissue to identify important proteins and biomarkers from patients with rhabdomyosarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment.
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma
- Trial name
- NCT01668095
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.